Troglitazone inhibits endothelial cell proliferation through suppression of casein kinase 2 activity

Biochemical and Biophysical Research Communications

Volumn 346, Issue 1, 2006, Pages 83-88

  Lee, Kuy Sook ^a   Park, Jin Hee ^a   Lee, Seahyoung ^b,c   Lim, Hyun Joung ^a   Jang, Yangsoo ^c   Park, Hyun Young ^a  

^a Korea National Institute of Health   (South Korea)

^b BK21 Project for Medical Science   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Akt; CK2; HUVEC; PPAR ; Proliferation; PTEN; Troglitazone

Indexed keywords

CASEIN KINASE II; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TROGLITAZONE;

AGONIST; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UMBILICAL VEIN;

CASEIN KINASE II; CELL MIGRATION INHIBITION; CELL PROLIFERATION; CELLS, CULTURED; CHROMANS; DICHLORORIBOFURANOSYLBENZIMIDAZOLE; ENDOTHELIAL CELLS; HUMANS; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; THIAZOLIDINEDIONES;

EID: 33744990834     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.05.069     Document Type: Article

References (21)

1. Gralinski M.R., Rowse P.E., and Breider M.A. Effects of troglitazone and pioglitazone on cytokine-mediated endothelial cell proliferation in vitro. J. Cardiovasc. Pharmacol. 31 (1998) 909-913
2. Goetze S., Bungenstock A., Czupalla C., Eilers F., Stawowy P., Kintscher U., Spencer-Hansch C., Graf K., Nurnberg B., Law R.E., Fleck E., and Grafe M. Leptin induces endothelial cell migration through Akt, which is inhibited by PPAR gamma-ligands. Hypertension 40 (2002) 748-754
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
4. Pepper M.S. Manipulating angiogenesis. From basic science to the bedside. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 605-619
5. Goetze S., Eilers F., Bungenstock A., Kintscher U., Stawowy P., Blaschke F., Graf K., Law R.E., Fleck E., and Grafe M. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochemical and Biophysical Research Communications 293 (2002) 1431-1437
6. Shiojima I., and Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res. 90 (2002) 1243-1250
7. Maehama T., and Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273 (1998) 13375-13378
8. Myers M.P., Stolarov J.P., Eng C., Li J., Wang S.I., Wigler M.H., Parsons R., and Tonks N.K. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc. Natl. Acad. Sci. USA 94 (1997) 9052-9057
9. Vazquez F., Ramaswamy S., Nakamura N., and Sellers W.R. Phosphorylation of the PTEN tail regulates protein stability and function. Mol. Cel. Biol. 20 (2000) 5010-5018
10. Litchfield D.W. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem. J. 369 (2003) 1-15
11. Pinna L.A. Casein kinase 2: an 'eminence grise' in cellular regulation?. Biochim. Biophys. Acta 1054 (1990) 267-284
12. Allende J.E., and Allende C.C. Protein kinases. 4. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation. FASEB J. 9 (1995) 313-323
13. Park Y., Freedman B.D., Lee E.J., Park S., and Jameson J.L. A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells. Diabetologia 46 (2003) 365-377
14. Denker S.P., and Barber D.L. Cell migration requires both ion translocation and cytoskeletal anchoring by the Na-H exchanger NHE1. J. Cell Biol. 159 (2002) 1087-1096
15. Davies M.A., Lu Y., Sano T., Fang X., Tang P., LaPushin R., Koul D., Bookstein R., Stokoe D., Yung W.K., Mills G.B., and Steck P.A. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res. 58 (1998) 5285-5290
16. Sun H., Lesche R., Li D.M., Liliental J., Zhang H., Gao J., Gavrilova N., Mueller B., Liu X., and Wu H. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA 96 (1999) 6199-6204
17. Weng L.P., Smith W.M., Dahia P.L., Ziebold U., Gil E., Lees J.A., and Eng C. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res. 59 (1999) 5808-5814
18. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., and Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
19. Huang J., and Kontos C.D. PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J. Biol. Chem. 277 (2002) 10760-10766
20. Torres J., and Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 276 (2001) 993-998
21. Miller S.J., Lou D.Y., Seldin D.C., Lane W.S., and Neel B.G. Direct identification of PTEN phosphorylation sites. FEBS Lett. 528 (2002) 145-153